Media coverage about Amphastar Pharmaceuticals (NASDAQ:AMPH) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Amphastar Pharmaceuticals earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.4328080695037 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have effected Accern’s analysis:
- Amphastar (AMPH) Q2 2018 Results – Earnings Call Transcript (seekingalpha.com)
- Momenta Pharmaceuticals (MNTA) Q2 2018 Earnings Conference Call Transcript (fool.com)
- MNK vs. AMPH: Which Stock Should Value Investors Buy Now? (finance.yahoo.com)
- Amphastar Pharmaceuticals (AMPH) Price Target Cut to $22.00 by Analysts at Needham & Company LLC (americanbankingnews.com)
- Amphastar Pharmaceuticals (AMPH) PT Lowered to $22 at Needham & Company (streetinsider.com)
A number of research firms recently issued reports on AMPH. Zacks Investment Research upgraded Amphastar Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, July 10th. ValuEngine raised Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 10th. BidaskClub raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Needham & Company LLC reduced their target price on Amphastar Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating for the company in a report on Friday. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $21.00.
NASDAQ AMPH traded up $0.14 on Friday, hitting $17.32. 147,896 shares of the company’s stock were exchanged, compared to its average volume of 136,294. The company has a current ratio of 1.94, a quick ratio of 1.53 and a debt-to-equity ratio of 0.11. Amphastar Pharmaceuticals has a fifty-two week low of $14.40 and a fifty-two week high of $20.45. The stock has a market capitalization of $800.83 million, a price-to-earnings ratio of 45.58, a PEG ratio of 2.57 and a beta of 1.40.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, August 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.08 by ($0.05). Amphastar Pharmaceuticals had a positive return on equity of 2.15% and a negative net margin of 3.39%. The business had revenue of $71.00 million for the quarter, compared to analyst estimates of $64.22 million. During the same quarter in the previous year, the firm posted $0.11 EPS. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. equities analysts forecast that Amphastar Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.
In other news, insider Jason B. Shandell sold 14,399 shares of the company’s stock in a transaction on Wednesday, July 11th. The stock was sold at an average price of $16.77, for a total transaction of $241,471.23. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Jack Y. Zhang purchased 25,000 shares of the stock in a transaction that occurred on Tuesday, May 15th. The stock was bought at an average price of $16.08 per share, with a total value of $402,000.00. Following the completion of the acquisition, the chief executive officer now owns 2,065,619 shares in the company, valued at approximately $33,215,153.52. The disclosure for this purchase can be found here. Insiders have sold a total of 32,649 shares of company stock worth $542,766 in the last quarter. 31.50% of the stock is currently owned by insiders.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.
Featured Article: What are Closed-End Mutual Funds?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.